Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma

Table 1 Current literature evaluating the role of ¹⁸F-fluorodexoyglucose positron emission tomography in staging hepatocellular carcinoma

First author	Year	No. of patients	Study design	Staging system	No. of patient with a change of stage by FDG PET	No. of patients with a change of treatment by FDG PET
Yoon et al[34]	2007	87	Not specified	TNM	4 patients (4.6%), 3 patients TNM IVa to IVb, 1 patient TNM III to IVa	Not specified
Kawamura et al[26]	2014	64	Retrospective	BCLC	16 patients (25%), 6 patients BCLC 0 to C, 7 patients BCLC A to C, 3 patients BCLC B to C	16 patients (25%)
Cho et al[35]	2014	457	Retrospective	BCLC and TNM	7 patients (1.5%), 6 patients BCLC A to C, 1 patient BCLC B to C	7 patients (1.5%)

FDG: ¹⁸F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.